Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus

Microorganisms

Jennifer Mayor¹  Sylvia Rothenberger¹  Olivier Engler² 

[1] Institute of Microbiology, University Hospital Center and University of Lausanne, CH-1011 Lausanne, Switzerland;Spiez Laboratory, Federal Office for Civil Protection, CH-3700 Spiez, Switzerland;

关键词: Hantaan virus;    ribavirin;    favipiravir;    combination therapy;   

DOI  :  10.3390/microorganisms9061306

来源: DOAJ

【 摘 要 】

Ecological changes, population movements and increasing urbanization promote the expansion of hantaviruses, placing humans at high risk of virus transmission and consequent diseases. The currently limited therapeutic options make the development of antiviral strategies an urgent need. Ribavirin is the only antiviral used currently to treat hemorrhagic fever with renal syndrome (HFRS) caused by Hantaan virus (HTNV), even though severe side effects are associated with this drug. We therefore investigated the antiviral activity of favipiravir, a new antiviral agent against RNA viruses. Both ribavirin and favipiravir demonstrated similar potent antiviral activity on HTNV infection. When combined, the efficacy of ribavirin is enhanced through the addition of low dose favipiravir, highlighting the possibility to provide better treatment than is currently available.

【 授权许可】

Unknown